FDA clears NuVasive's Cohere XLIF PEEK implant: 3 things to know

Written by Shayna Korol | November 08, 2018 | Print  |

NuVasive received FDA 510(k) clearance for the use of its Cohere Porous PEEK implant in eXtreme lateral interbody fusion procedures.

Here are three things to know:

1. Cohere is indicated for use with autograft and/or allograft in skeletally mature patients for thoracolumbar pathologies, such as degenerative disc disease, degenerative spondylolisthesis and degenerative scoliosis.

2. Cohere XLIF is designed to allow early incorporation of bone into the interbody spacer to prevent expulsion and promote fusion.

3. NuVasive expects to commercially launch Cohere XLIF in the U.S. in second quarter of 2019.

More articles on surface technology:
Spinal Elements earns FDA clearance for titanium surface coating
Titan Spine completes funding round: 3 things to know
Additive manufacturing company introduces new 3D-printed PEEK application — 3 things to know

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.